Menu
About
Company
Our Team
Investors
Science & Technology
Monovalent Protein Degraders
DELTA Discovery™ Platform
Publications & Presentations
Pipeline
Clinical Trials
Overview
SMARCA2
IKZF2
Contact
Discovery of potent and selective CDK2 molecular glue degraders for the treatment of HR+/HER2- breast cancer, and CCNE1 amplified tumors
Load More